Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Preclinical (animal) data Rodent studies suggest BPC-157 may: Promote blood vessel growth Enhance tendon fibroblast activity Reduce inflammation Protect gastrointestinal tissues However, these findings: Use doses far above any human equivalent Use controlled laboratory injuries Do not predict human efficacy 2
DITPA (3,5-Diiodothyropropionic Acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study
References "Demystifying Rejuran Salmon DNA," Onya Magazine , April 5, 2024 "Polynucleotide-Based Treatments For Various Facial Scars Including Combat Injuries," Journal of Dermatological Treatment , December 2024.
The current FDA status of BPC-157 is that of an unapproved drug compound with no active Investigational New Drug (IND) application accepted for human clinical trials as of available records
US$ 28.12
US$ 20.55
US$ 21.89
US$ 26.57
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
US$ 25.97
US$ 20.97
